



## Current Agreements

### Dealdoc

#### Licensing agreement for neurotoxin product candidates

Allergan  
Medytox

Sep 25 2013

## Licensing agreement for neurotoxin product candidates

<b>Companies:</b>	<a href="#">Allergan</a> <a href="#">Medytox</a>
<b>Announcement date:</b>	Sep 25 2013
<b>Deal value, US\$m:</b>	362 : sum of upfront and milestone payments

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

### Details

<b>Announcement date:</b>	Sep 25 2013
<b>Industry sectors:</b>	Bigbiotech Bigpharma Pharmaceutical
<b>Exclusivity:</b>	Exclusive
<b>Asset type:</b>	Compound
<b>Therapy areas:</b>	Dermatology » Cosmetics
<b>Technology types:</b>	Drug delivery » Parenteral » Injectable Small molecules
<b>Deal components:</b>	Licensing Discovery
<b>Stages of development:</b>	Preclinical Phase I
<b>Geographic focus:</b>	Worldwide
<b>Excluded geography:</b>	Asia » South Korea

### Financials

<b>Deal value, US\$m:</b>	362 : sum of upfront and milestone payments
<b>Upfront, US\$m:</b>	65 : upfront payment
<b>Milestones, US\$m:</b>	116.5 : upon achieving development milestones 180.5 : upon achieving commercialization milestones
<b>Royalty rates, %:</b>	n/d : on product sales

### Termsheet

Allergan and Medytox have entered into a license agreement pursuant to which, upon closing, Allergan will pay Medytox an upfront payment of U.S. \$65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product.

Allergan has also agreed to make additional contingent payments, including up to an aggregate of U.S. \$116.5 million upon achieving certain development milestones, up to an aggregate of U.S. \$180.5 million upon achieving certain commercialization milestones, and royalties on product sales.

The closing of the transaction is contingent on obtaining certain government approvals.

### Press Release

Jan 2014

#### Allergan, Inc. and Medytox, Inc. Complete Licensing Agreement

IRVINE, Calif. & SEOUL, South Korea--(BUSINESS WIRE)-- Allergan, Inc., (NYSE: AGN) and Medytox, Inc. today announced that they have closed the license agreement which was previously announced on September 25, 2013. Under the terms of the agreement, Allergan will pay Medytox an upfront cash payment of U.S. \$65 million within seven business days of closing and Medytox has granted Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. Pursuant to the agreement, Allergan has also agreed to make additional contingent payments, including up to an aggregate of U.S. \$116.5 million upon achieving certain development milestones, up to an aggregate of U.S. \$180.5 million upon achieving certain commercialization milestones, and royalties on product sales. About Allergan Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,400 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: [www.allergan.com](http://www.allergan.com). About Medytox Medytox is a research-based bio pharmaceutical company which developed a botulinum toxin product for the first time in Korea (the fourth in the world), and engages in the development, manufacture, marketing and sales of neurotoxin products as its main business. Since its establishment in 2000, Medytox has developed and evolved into a global world-class R&D company with the successful launch of its main neurotoxin product. Today, Medytox's neurotoxin product is sold in about 40 countries with millions of people having already received therapeutic or aesthetic treatments. We are committed to providing people safe and high-quality products through biotechnology for better health and quality of life. Medytox will continue extensive R&D investment on creative next generation technologies for future products to ensure we can continue to deliver on our commitments to patients and customers. For more information regarding Medytox, go to: [www.medytox.com](http://www.medytox.com)

---

#### Allergan, Inc. and Medytox, Inc. to Enter into Licensing Agreement

September 25, 2013

IRVINE, Calif. & SEOUL, Korea--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) and Medytox, Inc. today announced that they have entered into a license agreement pursuant to which, upon closing, Allergan will pay Medytox an upfront payment of U.S. \$65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. Pursuant to the agreement, Allergan has also agreed to make additional contingent payments, including up to an aggregate of U.S. \$116.5 million upon achieving certain development milestones, up to an aggregate of U.S. \$180.5 million upon achieving certain commercialization milestones, and royalties on product sales. The closing of the transaction is contingent on obtaining certain government approvals.

#### About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,200 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: [www.allergan.com](http://www.allergan.com).

#### About Medytox

Medytox is a research-based bio pharmaceutical company which developed a botulinum toxin product for the first time in Korea (the fourth in the world), and engages in the development, manufacture, marketing and sales of neurotoxin products as its main business. Since its establishment in 2000, Medytox has developed and evolved into a global world-class R&D company with the successful launch of its main neurotoxin product. Today, Medytox's neurotoxin product is sold in about 40 countries with millions of people having already received therapeutic or aesthetic treatments. We are committed to providing people safe and high-quality products through biotechnology for better health and quality of life. Medytox will continue extensive R&D investment on creative next generation technologies for future products to ensure we can continue to deliver on our commitments to patients and customers. For more information regarding Medytox, go to: [www.medytox.com](http://www.medytox.com).

#### Filing Data

*Not available.*

## **Contract**

*Not available.*